This post was originally published on this site
Regeneron Pharma announced earnings per share of $9.77 on revenue of $2.86B. Analysts polled by Investing.com anticipated EPS of $8.6 on revenue of $2.79B.
Regeneron Pharma shares are down 7% from the beginning of the year, still down 23.07% from its 52 week high of $747.42 set on April 8. They are outperforming the S&P 500 which is down 14.16% from the start of the year.
Regeneron Pharma’s report follows an earnings beat by UnitedHealth on July 15, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on July 19 with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
